OFFICE OF CANCER CLINICAL PROTEOMICS RESEARCH



Opportunities for CPACHE Investigators within CPTAC

Chris Kinsinger, PhD

Program Director

Office of Cancer Clinical Proteomics Research

NIH NATIONAL CANCER INSTITUTE

CPTAC in context



Imaging → Diagnosis

Genomics → Targeted therapy selection

Proteomics → Drug target

CPTAC in context



Imaging

Genomics

Proteomics

Improved Prevention, Diagnosis, Treatment

Clinical Proteomic Tumor Analysis Consortium

NIH NATIONAL CANCER INSTITUTE



CrCa: Global proteome reveals 2 new subtypes

Transcriptome Subtypes

- **MSI/CIMP**
- **Invasive**
- **CIN**

Proteome Subtypes

- **A**
- **B**
- **C**
- **D**
- **E**



Proteogenomic Data Analysis

Sequence-centric proteogenomics



Analysis of proteogenomic relationships



Integrative modeling of proteogenomic data



Data sharing and visualization



CPTAC III - U.S. Tissue Source Sites



- ABS
- Asterand
- Beaumont
- BioMatrix
- BioPartners, Inc.
- Boston Medical Center
- Cedars Sinai
- GBC
- IGC
- UCSD
- Walter Reed

- Baylor College of Medicine
- BioCell Analytics
- Cedars Sinai
- Johns Hopkins Cancer Center
- Memorial Sloan Kettering
- Meridian Health
- Moffitt Cancer Center
- Roswell Park
- Spectrum
- St. Joseph's
- Thomas Jefferson Univ.
- Univ. of Kansas
- Univ. of Pittsburgh
- Vanderbilt Univ.

CPTAC III - International Tissue Source Sites



Current Ethnicity Breakdown



CPTAC Tumor Types : Retrospective collection

Completed Phases:

Phase I: Technology Assessment

Phase II : Breast, Colon and Ovarian

Phase III completed tumor types: Uterine, Kidney and LungAdeno

Phase III (Still Accruing)

- Glioblastoma Multiforme
- Lung Squamous cell carcinoma
- Head and Neck Squamous cell carcinoma
- Pancreatic Ductal adenocarcinoma
- Cutaneous Melanoma
- Sarcomas
- Acute Myeloid Leukemia

CPTAC Biospecimen Accrual Requirements

CPTAC code	Cancer	Percent Tumor Nuclei	Percent Total Cellularity	Percent Necrosis	Maximum tumor Ischemic Time (min)	Accrual Status
CCRC	Clear Cell Renal Carcinomas	≥80%	≥50%	≤20%	30	Complete
UCEC	Uterine Corpus Endometrial Carcinoma	≥80%	≥50%	≤20%	30	Complete
LUAD	Lung Adeno Carcinoma	≥50%	≥50%	≤20%	45	Complete
PDA	Pancreatic Ductal Adenocarcinoma	No minimum; presence of tumor	No minimum	≤20%	50	Accruing
GBM	Glioblastoma Multiforme	≥60%	≥50%	≤50%	30	Accruing
LSCC	Lung Squamous Cell Carcinoma	≥50%	≥50%	≤20%	45	Accruing
HNSCC	Head and Neck Squamous Cell Carcinoma	≥80%	≥50%	≤20%	30	Accruing
CM	Cutaneous Melanoma	≥80%	≥50%	≤20%	30	Accruing
SAR	Sarcomas	≥80%	≥50%	≤20%	30	Accruing
AML	Acute Myeloid Leukemia	≥20% blasts	N/A	N/A	N/A	Accruing

Where to get the data?

- CPTAC data portal

- https://cptac-data-portal.georgetown.edu/cptacPublic/

- https://proteomics.cancer.gov and select “Data Portal”

- NCI’s GDC (Genomic Data)
  https://gdc.cancer.gov/



Contact

To participate in CPTAC as a TSS (Tissue source site), please contact

Mathangi Thiagarajan
CPTAC Project Manager
mathangi.thiagarajan@nih.gov

Chris Kinsinger
CPTAC Program Director
kinsingc@mail.nih.gov

Thank You

NIH NATIONAL CANCER INSTITUTE